Amarin Corp Plc (AMRN)

[sharinky]

Cantor Speaks

dough
@semodough
·
2m
CANT Per $AMRN brief, "The undeniable fact is that prior art did not point to any particular avenue— whether niacin, fibrate, omega-3 fatty acid mixture or individual component [of which there are at least seven found in Lovaza], or entirely new agent—as most promising to reduce
Quote Tweet

dough
@semodough
· 6h
CANT $AMRN Post trial briefs for AMRN &generic filers of Vascepa were filed 2/28).read briefs positively for AMRN. arguments remain focused on obviousness and inducement. burden to invalidate all of AMRN's patents is on generics. They have to prove that USPTO did not do its job


dough
@semodough
·
3m
TGs in severely hypertriglyceridemic patients without raising LDL-C. This is the antithesis of obvious."reaffirm OW rating think peak sales potential of Vascepa is underappreciated. upward earnings revisions to levels not reflected in FactSet consensus expectations BUY PT 35